News und Analysen

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43

Equities experienced a bear market in 2022, and although things have improved significantly over the past few months, it's impossible to say whether we are out of the woods. However, some

Buying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the

Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was

Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible

Anyone who has followed the stock market for years will attest the market isn't always rational in the near term. At the drop of a hat, a stock can receive more praise and price appreciation than it

We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the

A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global

Shares of Nutex Health (NASDAQ: NUTX) were up more than 12% Friday afternoon after being up as much as 24% earlier in the day. The company provides technology-driven healthcare management and

Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are

There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). The company beat earnings expectations for the first quarter as it has been slashing expenses, and recent clinical trials --

Provided that your portfolio is diversified to properly hedge against the risks associated with investing in stocks, it merely takes time, patience, and some well-thought-out picks to grow richer.

Axsome Therapeutics (NASDAQ: AXSM) wowed investors late last year with strong data from a phase 3 study of AXS-05, its candidate treatment for Alzheimer's disease agitation. AXS-05 met its primary

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

Shares of clinical-stage metabolism specialist Viking Therapeutics (NASDAQ: VKTX) were up by 12.4%, on abnormally high volume, as of 3:12 p.m. ET Tuesday afternoon. The big gain came after the

Biotech stocks have been on a wild ride this year. For instance, the bellwhether SPDR S&P Biotech ETF (NYSEMKT: XBI) has been up by as much as 9%, and down by as much as 12%, during just the first

Shares of Savara (NASDAQ: SVRA) rose more than 9% Tuesday morning after the company released first-quarter earnings. The stock is up more than 38% so far this year. Savara is a a clinical-stage phar

Johnson & Johnson (NYSE: JNJ) and UnitedHealth Group (NYSE: UNH) are considered great healthcare stocks to hold for the long term because of their size, steady cash flow, and above-average

Investors looking to secure a steadily growing passive income stream have all sorts of options, but few are easier to implement than buying dividend-paying stocks. That said, not every dividend

Image source: The Motley Fool.

CorMedix (NASDAQ: CRMD)Q1 2023 Earnings CallMay 15, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com